1. Vitamin D Related/Nuclear Receptor Immunology/Inflammation Apoptosis
  2. Androgen Receptor Pyroptosis Caspase Bcl-2 Family Apoptosis
  3. Triptophenolide

Triptophenolide  (Synonyms: Hypolide; (+)-Triptophenolide)

Cat. No.: HY-N0475 Purity: 99.98%
Handling Instructions Technical Support

Triptophenolide (Hypolide) is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC50 of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer.

For research use only. We do not sell to patients.

Triptophenolide

Triptophenolide Chemical Structure

CAS No. : 74285-86-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Triptophenolide:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Triptophenolide (Hypolide) is a colorless crystal isolated from the ethyl acetate extract of Tripterygium wilfordii. Triptophenolide is an orally active pan‑antagonist of the androgen receptor (AR) with an IC50 of 467 nM against human wild‑type AR. Triptophenolide reduces AR expression, inhibits AR nuclear translocation, downregulates prostate‑specific antigen mRNA levels, and suppresses the growth of AR‑positive prostate cancer cells. Triptophenolide shows anti-tumor effects against breast cancer by inhibiting cell proliferation and migration, inducing G1-phase arrest and apoptosis, repressing xenograft tumor growth. Triptophenolide inhibits pyroptosis, alleviates tissue inflammation, and ameliorates synovial injury. Triptophenolide can be used for the study of prostate cancer, rheumatoid arthritis and breast cancer[1][2][3].

IC50 & Target

Caspase 3

 

Caspase-9

 

Bax

 

Bak

 

Bim

 

Cellular Effect
Cell Line Type Value Description References
A2780 IC50
> 60 μM
Compound: Triptophenolide
Cytotoxicity against human A2780 cells assessed as cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as cell viability measured after 48 hrs by MTT assay
[PMID: 38964974]
A549 IC50
42.88 μM
Compound: 15
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
Cytotoxicity against human A549 cells after 48 hrs by MTT assay
[PMID: 27133593]
A549 IC50
> 100 μM
Compound: 43
Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
[PMID: 28011223]
Bcap37 IC50
22.4 μM
Compound: 15
Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
Cytotoxicity against human Bcap37 cells after 48 hrs by MTT assay
[PMID: 27133593]
Hep 3B2 IC50
22.21 μM
Compound: 15
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
Cytotoxicity against human Hep3B cells after 48 hrs by MTT assay
[PMID: 27133593]
HepG2 IC50
17.01 μM
Compound: 15
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
[PMID: 27133593]
MCF7 IC50
> 100 μM
Compound: 15
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
[PMID: 27133593]
PC-3 IC50
260 nM
Compound: Triptophenolide
Antagonist activity at wild type AR in human PC3 cells assessed as suppression of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay
Antagonist activity at wild type AR in human PC3 cells assessed as suppression of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay
[PMID: 27994731]
PC-3 IC50
388 nM
Compound: Triptophenolide
Antagonist activity at AR T877A mutant (unknown origin) transfected in human PC3 cells assessed as inhibition of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay
Antagonist activity at AR T877A mutant (unknown origin) transfected in human PC3 cells assessed as inhibition of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay
[PMID: 27994731]
PC-3 IC50
437 nM
Compound: Triptophenolide
Antagonist activity at AR W741C/T877A double mutant (unknown origin) transfected in human PC3 cells assessed as inhibition of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay
Antagonist activity at AR W741C/T877A double mutant (unknown origin) transfected in human PC3 cells assessed as inhibition of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay
[PMID: 27994731]
PC-3 IC50
480 nM
Compound: Triptophenolide
Antagonist activity at AR F876L mutant (unknown origin) expressed in human PC3 cells assessed as inhibition of DHT-induced receptor transactivation after 24 hrs by PSA-luciferase reporter gene assay
Antagonist activity at AR F876L mutant (unknown origin) expressed in human PC3 cells assessed as inhibition of DHT-induced receptor transactivation after 24 hrs by PSA-luciferase reporter gene assay
[PMID: 27994731]
PC-3 IC50
> 100 μM
Compound: 43
Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay
[PMID: 28011223]
SK-OV-3 IC50
> 100 μM
Compound: 43
Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay
[PMID: 28011223]
U-251 IC50
> 100 μM
Compound: 15
Cytotoxicity against human U251 cells after 48 hrs by MTT assay
Cytotoxicity against human U251 cells after 48 hrs by MTT assay
[PMID: 27133593]
In Vitro

Triptophenolide (50 nM-5 μM) potently inhibits DHT-induced transcriptional activity of wild-type AR, AR F876L, AR T877A and W741C+T877A AR double mutant in PC-3 cells, with IC50 values of 260 nM, 480 nM, 388 nM and 437 nM, respectively. It shows no agonistic activity toward these AR variants in the absence of DHT[1].
Triptophenolide (500 nM-5 μM) significantly downregulates prostate-specific antigen mRNA expression in LNCaP cells[1].
Triptophenolide (0.1-50.0 μM) dose-dependently inhibits the growth of AR-positive LNCaP prostate cancer cells, while having no significant effect on AR-negative PC-3 prostate cancer cell growth[1].
Triptophenolide (10 nM-10 μM) competitively binds to the androgen receptor ligand-binding domain in a cell-free system with an IC50 of 467 nM[1].
Triptophenolide (50 nM-5 μM; 24 h) dose-dependently suppresses androgen receptor protein expression in LNCaP cells after 24 hours of treatment, with significant effects at 500 nM and 5 μM[1].
Triptophenolide (5 μM) efficiently inhibits DHT-induced androgen receptor nuclear translocation in LNCaP cells[1].
Triptophenolide (0-400 μg/mL; 24/48 h) concentration- and time-dependently inhibits proliferation in MCF‑7 and MDA‑MB‑231 breast cancer cells[3].
Triptophenolide (180.3 μg/mL for MCF‑7 cells and 322.5 μg/mL for MDA‑MB‑231 cells; 48 h) significantly downregulates target gene mRNA levels as detected and reduces corresponding protein expression as determined in MCF‑7 and MDA‑MB‑231 breast cancer cells[3].
Triptophenolide (150 μg/mL; 24 h/48 h) induces apoptosis and G1-phase cell cycle arrest, and significantly inhibits migration in MCF-7 and MDA-MB-231 breast cancer cells[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line: LNCaP cells
Concentration: 50 nM, 500 nM, 5 μM
Incubation Time: 24 h
Result: Effectively suppressed AR protein expression in a dose-dependent manner.
Showed significant suppression at 500 nM and 5 μM.

RT-PCR[3]

Cell Line: MCF‑7 and MDA‑MB‑231 breast cancer cells
Concentration: 180.3 μg/mL for MCF‑7 cells and 322.5 μg/mL for MDA‑MB‑231 cells
Incubation Time: 48 h
Result: significantly upregulates the mRNA expression of multiple pro-apoptotic genes (e.g., BIM, BAK1, BAX, CASP3/9, TP53) and downregulates proliferation-associated genes such as AKT1 in both MCF-7 and MDA-MB-231 breast cancer cells.

Cell Viability Assay[3]

Cell Line: MCF‑7 and MDA‑MB‑231 breast cancer cells
Concentration: 0, 100, 200, 300, 400 μg/mL
Incubation Time: 24/48 h
Result: Inhibits proliferation in MCF‑7 and MDA‑MB‑231 breast cancer cells

Western Blot Analysis[3]

Cell Line: MCF‑7 and MDA‑MB‑231 breast cancer cells
Concentration: 180.3 μg/mL for MCF‑7 cells and 322.5 μg/mL for MDA‑MB‑231 cells
Incubation Time: 48 h
Result: significantly upregulated the expression of pro-apoptotic proteins BIM, BAK1, BAX, and CYCS in both MCF-7 and MDA-MB-231 breast cancer cells.

Cell Cycle Analysis[3]

Cell Line: MCF‑7 and MDA‑MB‑231 breast cancer cells
Concentration: 150 μg/mL
Incubation Time: 24 h/48 h
Result: Induced G1-phase cell cycle arrest in both MCF-7 and MDA-MB-231 breast cancer cells, with a marked increase in G1-phase cell proportion and a corresponding decrease in S-phase cell proportion.

Apoptosis Analysis[3]

Cell Line: MCF‑7 and MDA‑MB‑231 breast cancer cells
Concentration: 150 μg/mL
Incubation Time: 24 h/48 h
Result: Significantly induced apoptosis in both MCF-7 and MDA-MB-231 breast cancer cells, with markedly elevated total apoptosis rates.

Cell Proliferation Assay[3]

Cell Line: MCF‑7 and MDA‑MB‑231 breast cancer cells
Concentration: 150 μg/mL
Incubation Time: 24 h/48 h
Result: Significantly and time-dependently inhibited the migration of both MCF-7 and MDA-MB-231 breast cancer cells, with markedly reduced migration rates at 12 h and 24 h.
In Vivo

Triptophenolide (5-15 mg/kg; intragastric; once daily; 15 days) significantly reduces arthritis scores, suppresses synovial inflammatory factor levels, and alleviates synovial injury in collagen antibody-induced rheumatoid arthritis mice[2].
Triptophenolide (10 mg/kg; intraperitoneal injection; every 3 days; 21 days) significantly inhibits MCF-7 xenograft tumor growth, reduces tumor weight, and prolongs the survival of tumor-bearing BALB/c nude mice[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice (8-10-week-old)[3]
Dosage: 10 mg/kg
Administration: intraperitoneal injection; every 3 days; 21 days
Result: Significantly inhibited MCF-7 xenograft tumor growth, reduced tumor volume and weight, and prolonged the survival of tumor-bearing mice compared to the DMSO control group, with statistically significant improvements.
Animal Model: BALB/c (8-10-week-old)[2]
Dosage: 5 mg/kg; 15 mg/kg
Administration: intragastric; once daily; 15 days
Result: Significantly reduced mouse arthritis scores compared to the RA group at matching time points.
Suppressed synovial tissue expression of inflammatory factors IL-1β, IL-6, and TNF-α, with levels lower than those in the RA group.
Alleviated synovial injury and reduced inflammatory lesions in joint tissue, with statistically significant improvements compared to the RA group.
Molecular Weight

312.40

Formula

C20H24O3

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1C(CC[C@]2(C)C3=C(CC[C@]24[H])C(O)=C(C(C)C)C=C3)=C4CO1

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (320.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.2010 mL 16.0051 mL 32.0102 mL
5 mM 0.6402 mL 3.2010 mL 6.4020 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (8.00 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.98%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.2010 mL 16.0051 mL 32.0102 mL 80.0256 mL
5 mM 0.6402 mL 3.2010 mL 6.4020 mL 16.0051 mL
10 mM 0.3201 mL 1.6005 mL 3.2010 mL 8.0026 mL
15 mM 0.2134 mL 1.0670 mL 2.1340 mL 5.3350 mL
20 mM 0.1601 mL 0.8003 mL 1.6005 mL 4.0013 mL
25 mM 0.1280 mL 0.6402 mL 1.2804 mL 3.2010 mL
30 mM 0.1067 mL 0.5335 mL 1.0670 mL 2.6675 mL
40 mM 0.0800 mL 0.4001 mL 0.8003 mL 2.0006 mL
50 mM 0.0640 mL 0.3201 mL 0.6402 mL 1.6005 mL
60 mM 0.0534 mL 0.2668 mL 0.5335 mL 1.3338 mL
80 mM 0.0400 mL 0.2001 mL 0.4001 mL 1.0003 mL
100 mM 0.0320 mL 0.1601 mL 0.3201 mL 0.8003 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Triptophenolide
Cat. No.:
HY-N0475
Quantity:
MCE Japan Authorized Agent: